SHH and small cell lung carcinoma: Thus, Shh–GLI1 pathway inhibitors, such as cyclopamine, have been successfully tested in some cancer types such as medulloblastoma (51), pancreatic adenocarcinoma (52), small-cell lung cancer (SCLC) (53), gastric adenocarcinomas (54), and esophageal cancer (55).